Growth-stimulating pathways in lung cancer: Implications for targets of therapy

Clinical Lung Cancer

Volumn 2, Issue 4, 2001, Pages 299-306

  Sekine, I ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Farnesyl transferase inhibitor; G protein coupled receptors; Growth factor; Tyrosine kinase inhitor

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CGP 59326; CGP 69846A; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FARNESYL TRANS TRANSFERASE; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMATINIB; ISIS 2503; L 779450; LONAFARNIB; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE; RAS PROTEIN; SCATTER FACTOR; SOMATOMEDIN C; STEM CELL FACTOR; TIPIFARNIB; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AUTOCRINE EFFECT; BONE MARROW TOXICITY; CANCER CELL; CELL ACTIVITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEUROTOXICITY; PARACRINE SIGNALING; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 0034958238     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2001.n.013     Document Type: Article

References (77)

1. Epidemiology of lung cancer: A worldwide epidemic
2. The hallmarks of cancer
3. Growth factors in development, transformation, and tumorigenesis
4. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
5. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration
6. Structure and function of G protein-coupled receptors
7. Growth factors
8. Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease
9. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma
10. Sex-specific expression of gastrin-releasing peptide receptor: Relationship to smoking history and risk of lung cancer
11. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides
12. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer
13. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer
14. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer
15. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma
16. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism
17. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
18. Transforming growth factor alpha and epidermal growth factor
19. Growth factors and pulmonary epithelia
20. Role of epidermal growth factor in embryonic development
21. Role of an anti-epidermal growth factor receptor in treating cancer
22. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
23. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
24. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
25. The epidermal growth factor receptor and its inhibition in cancer therapy
26. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
27. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
28. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours
29. Novel anti-cancer agents in development: Exciting prospects and new challenges
30. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines
31. p185neu expression in human lung adenocarcinomas predicts shortened survival
32. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
33. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
34. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
35. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
36. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
37. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors
38. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
39. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo
40. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer
41. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer
42. The biology of stem cell factor and its receptor C-kit
43. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
44. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
45. Proteins regulating Ras and its relatives
46. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
47. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
48. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
49. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
50. A phase I and pharmacokinetic (PK) study of the farnesyl transferase inhibitor, R11577 in combination with gemcitabine (Gem)
51. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
52. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour weekly infusion to patients with advanced cancer
53. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
54. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
55. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway
56. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
57. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
58. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway
59. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)
60. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
61. CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule
62. Phospholipase C-gamma as a signal-transducing element
63. New insights into the regulation of protein kinase C and novel phorbol ester receptors
64. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
65. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
66. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha with carboplatin and paclitaxel in non-small cell lung cancer
67. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
68. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
69. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
70. A phase II study of bryostatin 1 in metastatic malignant melanoma
71. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century?
72. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
73. Preliminary results of a phase 2 study on protein kinase C inhibitor (CGP 41251) in low grade lymphoproliferative disorders
74. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein
75. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
76. Phase I study of UCN-01 by 3-hour infusion
77. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)